Last reviewed · How we verify
Abraxane (Induction)
Abraxane is a nanoparticle albumin-bound paclitaxel that stabilizes microtubules to inhibit cell division and induce apoptosis in cancer cells.
Abraxane is a nanoparticle albumin-bound paclitaxel that stabilizes microtubules to inhibit cell division and induce apoptosis in cancer cells. Used for Metastatic non-small cell lung cancer (induction therapy), Metastatic breast cancer, Pancreatic cancer.
At a glance
| Generic name | Abraxane (Induction) |
|---|---|
| Also known as | nab-paclitaxel |
| Sponsor | Celgene |
| Drug class | Microtubule stabilizer (taxane) |
| Target | β-tubulin / microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel binds to β-tubulin and prevents microtubule depolymerization, disrupting the mitotic spindle and halting cell cycle progression. The albumin-nanoparticle formulation improves drug delivery and reduces toxicity compared to conventional paclitaxel, allowing higher doses to reach tumor tissue more effectively.
Approved indications
- Metastatic non-small cell lung cancer (induction therapy)
- Metastatic breast cancer
- Pancreatic cancer
Common side effects
- Peripheral neuropathy
- Neutropenia
- Anemia
- Fatigue
- Nausea/vomiting
- Alopecia
Key clinical trials
- Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer (PHASE3)
- Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (PHASE3)
- To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement. (NA)
- A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (PHASE2)
- A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abraxane (Induction) CI brief — competitive landscape report
- Abraxane (Induction) updates RSS · CI watch RSS
- Celgene portfolio CI